CN108333352A - High-throughput detection method of O-type foot-and-mouth disease antibody - Google Patents
High-throughput detection method of O-type foot-and-mouth disease antibody Download PDFInfo
- Publication number
- CN108333352A CN108333352A CN201810084644.1A CN201810084644A CN108333352A CN 108333352 A CN108333352 A CN 108333352A CN 201810084644 A CN201810084644 A CN 201810084644A CN 108333352 A CN108333352 A CN 108333352A
- Authority
- CN
- China
- Prior art keywords
- serum
- mouth disease
- antigen
- detection method
- inhibiting rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 46
- 241000710198 Foot-and-mouth disease virus Species 0.000 title claims abstract description 32
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 title claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims abstract description 83
- 239000000427 antigen Substances 0.000 claims abstract description 41
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 36
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 19
- 239000007853 buffer solution Substances 0.000 claims description 18
- 238000010790 dilution Methods 0.000 claims description 16
- 239000012895 dilution Substances 0.000 claims description 16
- 239000012224 working solution Substances 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 14
- 238000003908 quality control method Methods 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 108010090804 Streptavidin Proteins 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 241001493546 Suina Species 0.000 claims description 4
- 235000015424 sodium Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 239000012898 sample dilution Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 abstract description 7
- 230000000903 blocking effect Effects 0.000 abstract description 6
- 230000004907 flux Effects 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 238000002965 ELISA Methods 0.000 description 8
- 238000007865 diluting Methods 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101800000440 Non-structural protein NS3A Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a high-throughput detection method of an O-type foot-and-mouth disease antibody, which can solve the technical problems that a liquid phase blocking E L ISA method is low in detection speed and detection flux and cannot meet the requirement of rapid high-flux detection under a large number of samples, and the detection method adopts a chemiluminescence immunoadsorption method to determine the relative light intensity R L U and the antigen contrast relative light intensity R L U of serum to be detected of a sample to be detected, and calculates the inhibition ratio PI according to the relative light intensity R L U and the antigen contrast relative light intensity R L U of the serum to be detected.
Description
Technical field
The present invention relates to technical field of biological, and in particular to a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody.
Background technology
Aftosa (foot-mouth disease, FMD) be the artiodactyl caused by foot and mouth disease virus (pig, ox, sheep,
Camel etc.) acute, the hot, contagious disease suffered from altogether, the disease is by World Organization for Animal Health (Office
International Des Epizooties, OIE) it is classified as first of A class infectious diseases, to the very harmful of Animal husbandry production.Disappear
It is the worldwide problem that national governments pay close attention to jointly to go out and control aftosa.
Serodiagnosis is one of the core technology in aftosa prevention, including Liquid-phase blocking ELISA, solid phase
The multinomial technologies such as competitive ELISA, nonstructural protein 3A BC antibody tests ELISA.Liquid-phase blocking ELISA is because of its good sensitivity
Property, specificity and stability are the aftosa serum diagnostic techniques being most widely used in the world.But this method is due to needing
Gradient dilution is carried out to sample, leads to it there are detection speeds slow, the low defect of detection flux cannot be satisfied under great amount of samples
The detection demand of fast high-flux.Lack the kit for carrying out high-throughput detection to foot-and-mouth disease antibody in existing market, mostly continues to use
Gradient dilution method carries out titration, and detection efficiency is low to have an immense impact on to aftosa epidemic monitoring.
Invention content
In view of the above-mentioned problems, the present invention provides a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody, can solve
Certainly Liquid-phase blocking ELISA method detection speed is slow, and detection flux is low, and the fast high-flux detection that cannot be satisfied under great amount of samples needs
The technical issues of asking.
Its technical solution is such, and a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody uses chemiluminescence to exempt from
The test serum relative light intensity RLU and antigen control relative light intensity RLU of epidemic disease determination of adsorption method sample to be tested, and according to be measured
Serum relative light intensity RLU and antigen control relative light intensity RLU calculate inhibiting rate PI, it is characterised in that:The chemiluminescence
It is dilute to carry out single for sample to be tested serum, negative quality controlled serum and positive quality control serum in the sample handling processes of immunoabsorption
It releases, the corresponding inhibiting rate PI of each potency serum counts the non-overlapping phenomenon in section under single dilutions multiple;The inhibiting rate PI passes through
Critical inhibiting rate corresponding with each potency serum compare the potency of determining test serum.
It is further, described that detection method includes the following steps:
(1) the sample to be tested serum after Sample dilution single dilutions, negative Quality Control blood are added in antigen-antibody reaction plate
The multiple of cleer and peaceful positive quality control serum, the single dilutions is 32 times;
(2) the biotinylated O-shaped viral antigen working solution of aftosa is added, while 4 antigen control holes are set, incubates, it is described
The antigen concentration of the biotinylated O-shaped viral antigen working solution of aftosa is 15 μ g/ml;
(3) it by the solution integral translation in reaction plate to the how anti-coating plate of rabbit, incubates, how anti-the coating of the rabbit coating plate be dense
Degree is 2 μ g/ml;
(4) board-washing, drying are added enzyme mark Streptavidin working solution to the how anti-plate of rabbit, incubate;
(5) substrate A and substrate B is added in board-washing, drying, measures relative light intensity RLU;
(6) judge, antigen control hole setting 4 is each, discards the peak and minimum of antigen control relative light intensity RLU, calculates
Remaining 2 hole average values are as antigen control RLU;
The corresponding critical inhibiting rate correspondence of each potency serum is as shown in the table
Potency | Inhibiting rate |
1:512 or more | >=96.0% |
1:256 | 90.3% |
1:128 | 79.8% |
1:64 | 60.8% |
1:32 | 50.2% |
1:16 | 31.7% |
1:8 and less | ≤ 17.7% |
Further, the how anti-coating plate of the rabbit is by the O-shaped foot and mouth disease virus rabbit polyvalent antibodies of 2 μ g/ml, 100 holes μ l/, packet
It is formed.
Further, the antigen-antibody reaction plate is U-shaped 96 hole antigen-antibody reaction plate.
Further, the sample diluting liquid is the PBS buffer solution containing 0.02%Tween20,1% pig negative serum, pH
For 7.2-7.4.
Further, the O-shaped viral antigen working solution of the biotinylated aftosa is the biotinylation containing 15 μ g/ml
The PBS buffer solution of antigen, 0.02%Tween-20,1%BSA, pH 7.2-7.4.
Further, the enzyme mark Streptavidin working solution is containing 5 μ g/ml of enzyme conjugates, 0.5wt%2- chloroacetamides
PBS buffer solution, pH 7.0-7.2, enzyme HRP.
Further, the negative quality controlled serum is the artiodactyl serum for being uninfected by foot and mouth disease virus, and inhibiting rate is more than
80%;The positive quality control serum is that O-shaped foot and mouth disease virus storms malicious animal blood serum, and inhibiting rate is less than 20%.
Further, the substrate A is to contain 1.26wt%N, dinethylformamide, 5.85mmol/L luminols,
The Tris-HCl buffer solutions of 9.86mmol/L tetraphenylboron sodiums and 1.06mg/L paracetamol, pH 8.8-9.0;The substrate
B is the Tris-HCl buffer solutions of the sodium perborate containing 0.615mg/mL, pH 4.8-5.0.
Further, the washing lotion is 20 times of concentration washing lotion, described 20 times of concentration washing lotion be containing 18wt%NaCl,
The Tris-HCl buffer solutions of 1wt%Tween20 and 1wt%Proclin300, pH 7.4-7.6.
The determination of the detection method of the present invention, logical serum optimum diluting multiple not only makes sample to be tested serum, negative matter
Control serum and positive quality control serum carry out single dilutions can effectively promote detection speed without carrying out gradient dilution, and
And improve detection flux;The foundation of kit evaluation criterion passes through inhibiting rate PI critical inhibition corresponding with each potency serum
Rate carries out the potency that comparison judges test serum, and deterministic process is intuitively quick, can further promote detection speed, and then the two
It is comprehensive always meeting the detection demand of the fast high-flux under great amount of samples.Through examining, ground with Lanzhou animal doctor using the present invention
Study carefully O-shaped foot-and-mouth disease antibody Liquid-phase blocking ELISA detection kit (standard reagent box) and meanwhile detect 88 parts of serum, this reagent
Box detection time is only 3 hours, accelerates for 40% (2 hours) compared with standard reagent box, be greatly improved detection efficiency and
Save manpower and materials cost.
Description of the drawings
Fig. 1-1~Fig. 1-4 is under 8 times, 16 times, the 32 times and 64 times extension rates for determining experiment of serum diluting multiple
Box figure.
Fig. 2-1 is the box figure of the foundation experiment of agent box evaluation criterion;Fig. 2-2~Fig. 2-8 is building for agent box evaluation criterion
Vertical experiment corresponds to potency 1:512、1:256、1:128、1:64、1:32、1:16、1:8 ROC curve.
Fig. 3 is the present invention and standard reagent box coincidence rate contrast experiment.
Specific implementation mode
Main agents explanation:
O-shaped foot-and-mouth disease virus antigen is purchased from middle peasant Witter bio tech ltd;
O-shaped foot and mouth disease virus rabbit polyvalent antibody is purchased from the Hangzhou bio tech ltd Qi Tai;
Negative quality controlled serum and positive quality control serum are provided by middle peasant Witter bio tech ltd;
Commercial ELISA Assay kit is the O-shaped foot-and-mouth disease antibody Liquid-phase blocking ELISA detection kit (mark of Lanzhou veterinary institute
Quasi- kit);
Totally 422 parts of serum sample derives from farm, for pig and the cow's serum sample of O-shaped aftosa vaccine is immunized;
The how anti-coating plate of rabbit is formed by the O-shaped foot and mouth disease virus rabbit polyvalent antibodies of 2 μ g/ml, 100 holes μ l/, coating;
Sample diluting liquid is the PBS buffer solution containing 0.02%Tween20,1% pig negative serum, pH 7.2-7.4;
The biotinylated O-shaped viral antigen working solution of aftosa is biotinylated antigen, 0.02%Tween- containing 15 μ g/ml
20, the PBS buffer solution of 1%BSA, pH 7.2-7.4;
Enzyme mark Streptavidin working solution is the PBS buffer solution containing 5 μ g/ml of enzyme conjugates, 0.5wt%2- chloroacetamides, and pH is
7.0-7.2, enzyme HRP;
Negative quality controlled serum is the artiodactyl serum for being uninfected by foot and mouth disease virus, and inhibiting rate is less than 20%;Positive quality control serum
Malicious animal blood serum is stormed for O-shaped foot and mouth disease virus, inhibiting rate is more than 80%;
Substrate A is to contain 1.26wt%N, dinethylformamide, 5.85mmol/L luminols, 9.86mmol/L tetraphenylboron sodiums and
The Tris-HCl buffer solutions of 1.06mg/L paracetamol, pH 8.8-9.0;Substrate B is sodium perborate containing 0.615mg/mL
Tris-HCl buffer solutions, pH 4.8-5.0;
The concentration washing lotion that washing lotion is 20 times, 20 times of concentration washing lotion is containing 18wt%NaCl, 1wt%Tween20 and 1wt%
The Tris-HCl buffer solutions of Proclin300, pH 7.4-7.6.
Embodiment 1
A kind of detection method of O-shaped foot-and-mouth disease antibody comprising following steps,
(1) use Sample dilution single dilute to 32 times of sample to be tested serum, negative quality controlled serum and positive quality control serum progress
It releases, antigen-antibody reaction plate is added with 50 holes μ l/;
(2) the biotinylated O-shaped viral antigen working solution of aftosa, 50 holes μ l/ are added, while 4 antigen control holes are set, add
Enter the antigen working solution in 100 holes μ l/, vibrate, 37 DEG C incubate 90 minutes;
(3) by the solution integral translation in reaction plate to the how anti-coating plate of rabbit, 50 holes μ l/, 37 DEG C incubate 40 minutes;
(4) enzyme mark Streptavidin working solution is added to the how anti-plate of rabbit in board-washing, drying, and 50 holes μ l/, 37 DEG C incubate 30 minutes;
(5) board-washing, drying are waited than mixed substrates A and substrate B, Substrate cocktail are added to the how anti-plate of rabbit, 100 holes μ l/ use
Chemiluminescence readings instrument measures relative light intensity RLU;
(6) yin and yang attribute of judgement test serum in 4 antigen control holes, is abandoned using antigen control inhibiting rate as criterion
Peak and minimum RLU values are removed, remaining 2 holes is calculated and is averaged RLU values as antigen control RLU values;
The corresponding critical inhibiting rate of each potency serum is as shown in table 1;
Table 1:The corresponding critical inhibiting rate of each potency serum
Potency | Inhibiting rate |
1:512 or more | >=96.0% |
1:256 | 90.3% |
1:128 | 79.8% |
1:64 | 60.8% |
1:32 | 50.2% |
1:16 | 31.7% |
1:8 and less | ≤ 17.7% |
Inhibiting rate PI by critical inhibiting rate corresponding with each potency serum compare the potency of determining test serum.
Sample to be tested serum, antigen control, the layout of negative quality controlled serum and positive quality control serum are as shown in table 2.
Table 2:Laboratory reference is laid out
Embodiment 2
The determination of 2.1 rabbits mostly anti-best peridium concentration and antigen best effort concentration
Determine that rabbit resists best peridium concentration and antigen best effort concentration more using Checkerboard titration method.The how anti-peridium concentration of rabbit by
32 twice of serial dilution of μ g/ml to 1 μ g/ml are laterally coated with, and antigen concentration is by 40 twice of serial dilution of μ g/ml to 0.08 μ g/ml
Longitudinal sample-adding is finally considering the sufficiently large (RLU of signal value requirement>50000000) and antigen concentration is under corresponding peridium concentration
The singular point of variation selects peridium concentration for 2 μ g/ml, and corresponding antigen working concentration is 15 μ g/ml, and titration results are as shown in table 3.
Table 3:Titration results
The determination of 2.2 serum diluting multiples
(peridium concentration is 2 μ g/ml, and corresponding antigen working concentration is 15 μ g/ml), detection 24 are tested by above-mentioned determining condition
The Swine serum sample of part known background, serum titer are as shown in table 4.It is dilute to 8 times, 16 times, 32 times and 64 times of detection serum progress
Detection is released, the inhibiting rate of sample serum under each extension rate is calculated, using box figure to different potency serum under each dilution
Inhibiting rate is distinguished situation and is analyzed, and as shown in Fig. 1-1~Fig. 1-4, comments first box figure main part overlapping cases
Valence, it can be seen from the figure that, extension rate 1:When 8, potency is 1:Its box portion of 22 or more serum has apparent overlapping;It is dilute
It is 1 to release multiple:When 16, potency is 1:45 have the overlapping of part with upper box;Extension rate is 1:When 64, potency 1:22 and 1:
45 serum box portion is substantially overlapping;And it is 1 in extension rate:When 32, it can be seen that box portion has no weight between each potency
Folded situation, only in potency 1:45 and 1:There are crossing instances between 90;Secondly, bound is verified, bound is set using 95%
Letter section is determined, without the use of the maximum value that is shown in box figure and minimum as standard, 1:When 32 dilution, potency 1:
The number of photons upper limit of 90 detections is 2.09E+007, is less than potency 1:The number of photons lower limit (2.10E+007) of 45 detections;It is final true
Fixed 1:32 be best serum diluting multiple, i.e., when 32 times dilutions, each potency serum inhibiting rate is distinguished apparent, can be carried out to serum good
Good identification.
The corresponding inhibiting rate PI statistics non-overlapping phenomenon in section of each potency serum, which refers to, under single dilutions multiple detects serum
Single dilutions are carried out (preferably 32 times in embodiment) under a certain extension rate, (embodiment uses box through statistical analysis
Map analysis), the corresponding statistics section of each potency serum inhibiting rate distinguish it is apparent, it is non-overlapping.
Table 4:Virus monitory sample distribution table
Potency | Number of samples |
1:4 | 2 |
1:11 | 2 |
1:22 | 3 |
1:45 | 4 |
1:90 | 6 |
1:180 | 3 |
1:360 | 4 |
The foundation of 2.3 doses of box evaluation criterions
Tested that (peridium concentration is 2 μ g/ml, and corresponding antigen working concentration is 15 μ g/ml, serum using above-mentioned determining condition
Extension rate is 32 times), 174 parts of known background serum are detected altogether.The inhibiting rate of testing result is analyzed using box figure,
As shown in Fig. 2-1, using ROC curve, the critical inhibiting rate value of each potency is determined, as shown in Fig. 2-2~Fig. 2-8.The result shows that
It is distinguished obviously between 174 parts of each potency of serum of detection, without overlapping cases, has confirmed 2.2 results.ROC curve figure simultaneously
It shows that area under the curve is 0.833~0.978, is all higher than 0.5, show that curve has very high accuracy to the judgement of critical value.
Finally, the critical inhibiting rate that each potency is determined by Youden index establishes the result criterion of the present invention with this, such as
Shown in table 5.
Table 5:The corresponding critical inhibiting rate correspondence of each potency serum
Potency | Inhibiting rate |
1:512 or more | >=96.0% |
1:256 | 90.3% |
1:128 | 79.8% |
1:64 | 60.8% |
1:32 | 50.2% |
1:16 | 31.7% |
1:8 | 17.7% |
Embodiment 3
3.1 coincidence rates are tested
In order to be verified to kit performance, has chosen 244 parts of field serum and (refer to by farm, withdraw to the sources of students such as farm
Serum) be measured with the condition of above-mentioned determination, and simultaneously use Lanzhou veterinary institute O-shaped foot-and-mouth disease antibody liquid phase block
ELISA detection kit is detected as a comparison, and the results are shown in Figure 3, the results showed that, the two correlation is y=0.9435+
0.0831, correlation coefficient r 0.9551 belongs to highly relevant, illustrates that the present invention has good specificity and sensibility, detection knot
Fruit has very high confidence level.
Embodiment of the present invention is interpreted as illustrative, to be not intended to limit the present invention protection domain, for this field
For technical staff, under the premise of without departing substantially from spirit and scope of the present invention, this is still fallen within to all adjustment that the present invention makes
The protection domain of invention.
Claims (9)
1. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody, uses chemiluminescence immunoassay determination of adsorption method sample to be tested
Test serum relative light intensity RLU and antigen control relative light intensity RLU, and according to test serum relative light intensity RLU and
Antigen control relative light intensity RLU calculates inhibiting rate PI, it is characterised in that:The sample treatment of the chemiluminescence immunoassay absorption method
Sample to be tested serum, negative quality controlled serum and positive quality control serum carry out single dilutions in the process, are respectively imitated under single dilutions multiple
The corresponding inhibiting rate PI of valence serum counts the non-overlapping phenomenon in section;The inhibiting rate PI passes through corresponding critical with each potency serum
Inhibiting rate compare the potency of determining test serum.
2. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:The inspection
Survey method includes the following steps:
(1) the sample to be tested serum after Sample dilution single dilutions, negative Quality Control blood are added in antigen-antibody reaction plate
The multiple of cleer and peaceful positive quality control serum, the single dilutions is 32 times;
(2) the biotinylated O-shaped viral antigen working solution of aftosa is added, while 4 antigen control holes are set, incubates, it is described
The antigen concentration of the biotinylated O-shaped viral antigen working solution of aftosa is 15 μ g/ml;
(3) it by the solution integral translation in reaction plate to the how anti-coating plate of rabbit, incubates, how anti-the coating of the rabbit coating plate be dense
Degree is 2 μ g/ml;
(4) board-washing, drying are added enzyme mark Streptavidin working solution to the how anti-plate of rabbit, incubate;
(5) substrate A and substrate B is added in board-washing, drying, measures relative light intensity RLU;
(6) judge, antigen control hole setting 4 is each, discards the peak and minimum of antigen control relative light intensity RLU, calculates
Remaining 2 hole average values are as antigen control RLU;
Inhibiting rate
The corresponding critical inhibiting rate correspondence of each potency serum is as shown in the table
3. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:The rabbit
Mostly anti-coating plate is formed by the O-shaped foot and mouth disease virus rabbit polyvalent antibodies of 2 μ g/ml, 100 holes μ l/, coating.
4. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:The sample
Product dilution is the PBS buffer solution containing 0.02%Tween20,1% pig negative serum, pH 7.2-7.4.
5. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:The life
The O-shaped viral antigen working solution of aftosa of object element is the biotinylated antigen containing 15 μ g/ml, 0.02%Tween-20,1%
The PBS buffer solution of BSA, pH 7.2-7.4.
6. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:The enzyme
Mark Streptavidin working solution is the PBS buffer solution containing 5 μ g/ml of enzyme conjugates, 0.5wt%2- chloroacetamides, pH 7.0-
7.2, enzyme HRP.
7. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:Described the moon
Property quality controlled serum be the artiodactyl serum for being uninfected by foot and mouth disease virus, inhibiting rate be less than 20%;The positive quality control serum is O
The malicious animal blood serum of type foot and mouth disease virus storming, inhibiting rate are more than 80%.
8. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:The bottom
Object A is to contain 1.26wt%N, dinethylformamide, 5.85mmol/L luminols, 9.86mmol/L tetraphenylboron sodiums and
The Tris-HCl buffer solutions of 1.06mg/L paracetamol, pH 8.8-9.0;The substrate B is to cross boron containing 0.615mg/mL
The Tris-HCl buffer solutions of sour sodium, pH 4.8-5.0.
9. a kind of high-flux detection method of O-shaped foot-and-mouth disease antibody according to claim 1, it is characterised in that:It is described to wash
The concentration washing lotion that liquid is 20 times, described 20 times of concentration washing lotion is containing 18wt%NaCl, 1wt%Tween20 and 1wt%
The Tris-HCl buffer solutions of Proclin300, pH 7.4-7.6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810084644.1A CN108333352A (en) | 2018-01-29 | 2018-01-29 | High-throughput detection method of O-type foot-and-mouth disease antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810084644.1A CN108333352A (en) | 2018-01-29 | 2018-01-29 | High-throughput detection method of O-type foot-and-mouth disease antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108333352A true CN108333352A (en) | 2018-07-27 |
Family
ID=62925999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810084644.1A Pending CN108333352A (en) | 2018-01-29 | 2018-01-29 | High-throughput detection method of O-type foot-and-mouth disease antibody |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108333352A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110187105A (en) * | 2019-06-25 | 2019-08-30 | 艾军 | A kind of B-ELISA kit and preparation method detecting ox, the O-shaped antibody of sheep foot and mouth disease virus |
CN110297091A (en) * | 2019-07-17 | 2019-10-01 | 中国农业科学院兰州兽医研究所 | A kind of multiple tube-type chemical luminescence detection kit of I type antibody of aftosa O, A, Asia |
CN112881710A (en) * | 2021-02-04 | 2021-06-01 | 中国农业科学院兰州兽医研究所 | Inhibition ELISA method for detecting foot-and-mouth disease virus antibody and application thereof |
CN113391061A (en) * | 2021-06-16 | 2021-09-14 | 王婷楠 | Application of animal immune antibody in preparation of medicine for detecting animal immunity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102662062A (en) * | 2012-04-17 | 2012-09-12 | 中国农业科学院兰州兽医研究所 | Monoclonal antibody blocking enzyme-linked immunosorbent assay (ELISA) kit and method for detecting nonstructural protein (NSP) antibody of foot-and-mouth disease virus (FMDV) |
CN106226519A (en) * | 2016-07-18 | 2016-12-14 | 洛阳现代生物技术研究院有限公司 | A kind of O type antibodies against foot-and-mouth disease virus chemiluminescence detection kit |
CN106501512A (en) * | 2016-11-22 | 2017-03-15 | 盐城拜明生物技术有限公司 | Foot-and-mouth disease antibody detection kit, detection method and application thereof |
CN106596932A (en) * | 2016-11-25 | 2017-04-26 | 中国农业科学院兰州兽医研究所 | Chemiluminescence detection kit of swine foot-and-mouth disease 3ABC and 2C antibodies |
-
2018
- 2018-01-29 CN CN201810084644.1A patent/CN108333352A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102662062A (en) * | 2012-04-17 | 2012-09-12 | 中国农业科学院兰州兽医研究所 | Monoclonal antibody blocking enzyme-linked immunosorbent assay (ELISA) kit and method for detecting nonstructural protein (NSP) antibody of foot-and-mouth disease virus (FMDV) |
CN106226519A (en) * | 2016-07-18 | 2016-12-14 | 洛阳现代生物技术研究院有限公司 | A kind of O type antibodies against foot-and-mouth disease virus chemiluminescence detection kit |
CN106501512A (en) * | 2016-11-22 | 2017-03-15 | 盐城拜明生物技术有限公司 | Foot-and-mouth disease antibody detection kit, detection method and application thereof |
CN106596932A (en) * | 2016-11-25 | 2017-04-26 | 中国农业科学院兰州兽医研究所 | Chemiluminescence detection kit of swine foot-and-mouth disease 3ABC and 2C antibodies |
Non-Patent Citations (3)
Title |
---|
BLANCA ROBIOLO 等: "Quantitative single serum-dilution liquid phase competitive blocking ELISA for the assessment of herd immunity and expected protection against foot-and-mouth disease virus in vaccinated cattle", 《JOURNAL OF VIROLOGICAL METHODS》 * |
GAURAV KUMAR SHARMA 等: "Quantitative single dilution liquid phase blocking ELISA for sero-monitoring of foot-and-mouth disease in India", 《BIOLOGICALS》 * |
毛春生和尹风 阁: "血清单稀释ELISA检测鸡ILT抗体的初步研究", 《河南农业大学学报》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110187105A (en) * | 2019-06-25 | 2019-08-30 | 艾军 | A kind of B-ELISA kit and preparation method detecting ox, the O-shaped antibody of sheep foot and mouth disease virus |
CN110187105B (en) * | 2019-06-25 | 2022-03-22 | 艾军 | B-ELISA kit for detecting O-type antibody of foot-and-mouth disease virus of cattle and sheep and preparation method thereof |
CN110297091A (en) * | 2019-07-17 | 2019-10-01 | 中国农业科学院兰州兽医研究所 | A kind of multiple tube-type chemical luminescence detection kit of I type antibody of aftosa O, A, Asia |
CN110297091B (en) * | 2019-07-17 | 2020-12-01 | 中国农业科学院兰州兽医研究所 | Multi-tube chemiluminescence detection kit for foot-and-mouth disease O, A, Asia I-type antibody |
CN112881710A (en) * | 2021-02-04 | 2021-06-01 | 中国农业科学院兰州兽医研究所 | Inhibition ELISA method for detecting foot-and-mouth disease virus antibody and application thereof |
CN112881710B (en) * | 2021-02-04 | 2022-04-22 | 中国农业科学院兰州兽医研究所 | Inhibition ELISA method for detecting foot-and-mouth disease virus antibody and application thereof |
CN113391061A (en) * | 2021-06-16 | 2021-09-14 | 王婷楠 | Application of animal immune antibody in preparation of medicine for detecting animal immunity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108333352A (en) | High-throughput detection method of O-type foot-and-mouth disease antibody | |
CN106226516B (en) | A kind of hyperbola calibrates quantitative immunochromatographic detection method | |
CN105548565A (en) | Kit for detecting trypanosoma cruzi antibody as well as preparation and application thereof | |
CN103592445A (en) | Kit for detecting procalcitonin | |
CN101975859A (en) | Magnetic microparticle separation chemiluminescent immunoassay detection method for hepatitis B virus surface antigen | |
Liu et al. | An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 neutralizing antibody levels in COVID-19 patients and vaccinees | |
CA2882151A1 (en) | Chemiluminescent protein chip, method and kit for detecting seroglycoid fucosylation index | |
CN102507918A (en) | Kit for determining anti-cyclic citrullinated peptide (Anti-CCP) antibody | |
CN108519487A (en) | A kind of quantitative detecting method and detection kit of interleukin-6 | |
CN104237520A (en) | Hepatitis c virus antigen-antibody joint detection reagent box and preparation method thereof | |
CN110261623A (en) | A kind of detection sheep echinococcosis granulosa antibody indirect ELISA detection kit and its application | |
Piec et al. | Performance of SARS-CoV-2 serology tests: Are they good enough? | |
CN101995466A (en) | Diagnostic kit for Newcastle disease virus antibody | |
Chen et al. | A rapid test for the detection of influenza A virus including pandemic influenza A/H1N1 2009 | |
Mitamura et al. | Evaluation of a new immunochromatographic assay for rapid identification of influenza A, B, and A (H1N1) 2009 viruses | |
CN104714028B (en) | Immunodetection method for detecting IgM antibody | |
CN105223360B (en) | Kit for detection and identification of normal plasma cell and clonal plasma cell and application thereof | |
Chen et al. | Rapid diagnostic tests for identifying avian influenza A (H7N9) virus in clinical samples | |
CN102368068A (en) | Kit for detecting chlamydia pneumoniae IgM antibody | |
WO2021185034A1 (en) | Novel coronavirus nucleic acid rapid hybridization capture immunofluorescence detection kit, and preparation method and detection method | |
CN104914244A (en) | Kit for combined detection of hepatitis C virus antigen and antibody through chemiluminescence | |
CN104360074A (en) | Time-resolved fluorescence immunoassay method of Lp-PLA2 and kit | |
Liu et al. | Simultaneous detection of four nitrofuran metabolites in honey using high-throughput suspension array technology | |
Mousa et al. | Application and validation of SARS-CoV-2 RBD neutralizing ELISA assay | |
CN102433339B (en) | HCV Nucleic acid aptamer and application thereof in preparing HCV-cAg detection kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180727 |
|
RJ01 | Rejection of invention patent application after publication |